Combination therapy with mogamulizumab and pegylated liposomal doxorubicin in tumoral advanced-stage mycosis fungoides/Sézary syndrome: a report of two patients

Two patients with advanced-stage mycosis fungoides/Sézary syndrome experienced deep blood responses with mogamulizumab, including peripheral blood minimal residual disease negativity, but developed progressive tumoral skin disease. The addition of pegylated liposomal doxorubicin resulted in rapid tumour regression while maintaining blood disease control. These cases highlight a compartment-directed therapeutic strategy and suggest complementary activity of both agents in advanced cutaneous T-cell lymphoma.